# Chronic Granulomatous Disease

Confirm suspected chronic granulomatous disease with neutrophil oxidative-burst testing, identify the genetic defect, aggressively investigate characteristic bacterial or fungal infections, control inflammatory complications without missing infection, and consider allogeneic hematopoietic stem-cell transplantation as potentially curative.

**Clinical question:** How should physicians confirm, evaluate, and manage chronic granulomatous disease and its infectious and inflammatory complications?

Updated: 2026-08-24T16:55:17.029064+00:00

## What matters in practice
- Order a dihydrorhodamine oxidative-burst assay when recurrent or unusually severe infection involves CGD-associated bacteria or molds; confirm the molecular defect with genetic testing after an abnormal functional result. [3][21][23]
- Treat fever, focal pulmonary disease, lymphadenitis, hepatic abscess, osteomyelitis, or deep soft-tissue infection as a potentially serious bacterial or fungal event and obtain material for microbiologic diagnosis whenever feasible. [5][15]
- Pulmonary lesions in CGD require early chest CT and an invasive-fungal workup; Aspergillus-associated CT abnormalities may include nodules, halo sign, or cavitation, while cultures can be negative. [2]
- Differentiate active infection from sterile inflammatory disease before escalating immunosuppression for colitis or obstructive granulomatous disease. [5][16][17]
- Long-term antibacterial and antifungal prophylaxis, with interferon-gamma therapy in conventional management, reduces the burden of recurrent infection but does not correct the phagocyte defect. [9][10]
- Allogeneic hematopoietic stem-cell transplantation can cure CGD; referral to a transplant center is appropriate early in patients with severe infections, refractory inflammation, or substantial disease burden. [11][12]

## Identify the infection and inflammation pattern that warrants oxidative-burst testing

Test before labeling recurrent infection as nonspecific immune dysfunction.

Suspect CGD in a child or adult with recurrent, severe, persistent, or deep bacterial and fungal infections, particularly pneumonia, suppurative lymphadenitis, pyoderma, liver abscess, osteomyelitis, or recurrent deep-tissue abscesses. The most characteristic organisms include Staphylococcus aureus, Serratia marcescens, Burkholderia cepacia complex, Nocardia species, and Aspergillus species. [5][15]

Escalate suspicion when infection is unusually destructive, multifocal, refractory to standard antibacterial therapy, or caused by uncommon organisms. CGD-associated osteomyelitis may involve small bones of the hands or feet and can affect multiple sites; obtain imaging of symptomatic sites and pursue aspiration or biopsy of purulent material for organism identification. [15]

Do not restrict testing to infectious presentations. CGD can present with inflammatory bowel disease-like colitis, noninfectious granulomas causing gastrointestinal or urinary tract obstruction, or other dysregulated inflammatory manifestations. In a patient with early-onset inflammatory disease plus a compatible infection history, assess for CGD rather than treating presumed idiopathic inflammatory bowel disease alone. [16][17][19]
- Ask specifically about prior Aspergillus, Nocardia, Burkholderia, Serratia, recurrent staphylococcal infection, hepatic abscess, and deep lymphadenitis. [5][15]
- Ask about exposure to decaying organic material or mulch in patients with acute pulmonary symptoms, because fungal exposure can provoke a marked inflammatory pulmonary response in CGD. [15]
- Document family history of affected males, carrier status, early severe infection, or prior transplant; CGD results from genetic defects affecting the NADPH oxidase complex. [5][14]

*Clinical patterns that should trigger evaluation for CGD. [5][15][16][17]*

| Presentation | Discriminator | Next action |
| --- | --- | --- |
| Recurrent pneumonia or focal lung lesion | Infection with Aspergillus, Nocardia, Burkholderia, Serratia, or severe recurrent staphylococcal disease. [5][15] | Order DHR oxidative-burst testing; obtain chest CT and directed microbiology if active pulmonary disease is present. [2][3][21] |
| Deep abscess, suppurative lymphadenitis, or liver abscess | Persistent or recurrent infection despite usual therapy; unusual or difficult-to-identify pathogens increase concern. [15][24] | Drain or aspirate when feasible and send bacterial, fungal, and appropriate molecular testing; obtain DHR testing. [15][24] |
| Multifocal or small-bone osteomyelitis | CGD osteomyelitis may involve small bones of hands or feet and multiple sites. [15] | Image involved sites, obtain microbiologic material when possible, and assess oxidative burst. [15][21] |
| Colitis or obstructive granulomatous disease | Inflammatory bowel disease-like colitis or noninfectious gastrointestinal or urinary obstruction can occur in CGD. [16][17] | Exclude infection and obtain DHR testing when the phenotype or history is compatible. [3][16] |

## Confirm defective phagocyte oxidative burst and define the inherited disorder

Functional confirmation should precede genotype-directed counseling and transplant planning.

Use a flow cytometry-based dihydrorhodamine 123 assay as the practical diagnostic test for suspected CGD. An abnormal DHR result is consistent with CGD because affected phagocytes fail to generate a normal oxidative burst; nitroblue tetrazolium testing is an alternative historical functional assay. [3][21][22][23]

After an abnormal oxidative-burst study, obtain molecular genetic testing to confirm the disease-causing defect and support inheritance assessment. CGD reflects defects in components of the NADPH oxidase complex, and clinical severity varies by genotype; p22phox and p67phox defects have been associated with more severe complications, whereas p47phox mutations may produce a milder phenotype. [3][5][15]

Interpret an abnormal DHR assay in clinical context rather than as an isolated laboratory finding. A compatible phenotype includes recurrent serious bacterial or fungal infection and exaggerated granulomatous inflammation; genetic confirmation is particularly important for family counseling, identification of carrier status, and selection discussions for curative therapy. [3][5][14]
- Send DHR testing promptly during evaluation of a characteristic infection; do not defer functional testing until the acute infection has resolved. [21][23]
- Use genetic confirmation after an abnormal DHR or nitroblue tetrazolium result. [3]
- Assess relatives when an inherited CGD defect is identified, particularly where X-linked disease or carrier status is plausible. [14]

*Diagnostic sequence for suspected CGD. [3][5][21][23]*

| Step | Test or finding | Interpretation and action |
| --- | --- | --- |
| 1 | Clinical phenotype: recurrent severe bacterial or fungal infection, granuloma formation, or inflammatory disease. [5][17] | Proceed to functional neutrophil oxidative-burst testing. [21][23] |
| 2 | DHR 123 flow cytometry assay. [21][23] | An abnormal result supports CGD and should prompt molecular confirmation. [3] |
| 3 | Nitroblue tetrazolium assay. [3][13] | Abnormal reduction testing also supports defective oxidative burst; use molecular testing for confirmation. [3] |
| 4 | Genetic testing. [3] | Defines the molecular diagnosis, informs inheritance assessment, and contributes to risk stratification and definitive-therapy planning. [3][15] |

## Investigate focal infection aggressively and obtain tissue when possible

Negative routine cultures do not exclude invasive fungal disease.

In CGD with fever or focal symptoms, localize infection early with site-directed imaging and obtain microbiologic material before narrowing therapy. For abscesses, lymph nodes, bone lesions, and other purulent collections, aspiration is important for pathogen identification; send bacterial and fungal cultures and use molecular identification when routine methods fail. [15][24]

For pulmonary disease, obtain chest CT rather than relying on nonspecific symptoms or plain radiography alone. Invasive aspergillosis may produce nodular lesions, halo sign, or cavitation, but these findings are not specific; blood and respiratory cultures are often negative. [2]

Use fungal biomarkers as adjuncts rather than replacements for imaging and sampling. In high-risk hematologic malignancy or hematopoietic stem-cell transplant populations with compatible clinical and radiologic findings, serum galactomannan positivity has been defined as at least 0.5 on two separate samples or at least 1.0 on one sample; BAL fluid positivity has been defined as at least 1.0 on two aliquots from one BAL specimen. Extrapolate these thresholds cautiously in CGD, where diagnostic performance is not established by this qualification. [2]

When a pathogen is not identified despite ongoing disease, maintain suspicion for unusual CGD-associated organisms. Methylotroph infections have occurred in CGD and required 16S rRNA gene sequencing for correct diagnosis; affected patients often required prolonged antimicrobial therapy and some required surgery. [24]
- Drain or aspirate accessible abscesses and send specimens for bacterial and fungal evaluation rather than relying on blood cultures. [15]
- Use bronchoscopy with BAL when pulmonary disease is persistent or imaging suggests invasive fungal infection and a lower-respiratory specimen is needed. [2]
- Request molecular identification, including 16S rRNA sequencing, for unresolved infections with atypical culture results or suspected methylotrophs. [24]
- Involve infectious diseases and clinical immunology early for deep infection, suspected mold disease, recurrent infection despite prophylaxis, or culture-negative progressive disease. [5][24]

### Inflammation versus uncontrolled infection

Colitis, granulomatous obstruction, and pulmonary inflammatory manifestations may reflect CGD-associated immune dysregulation, but infection can coexist or mimic inflammatory disease. Before intensifying anti-inflammatory treatment, reassess for focal infection using targeted imaging, cultures, and tissue sampling where clinically feasible. [16][17]
- Treat a new focal lesion, persistent fever, or progressive inflammatory marker elevation as an indication to re-open the infectious workup rather than presuming sterile inflammation. [5][15]
- For obstruction from suspected granulomatous disease, define the anatomic site and exclude an infectious mass or abscess before procedural or anti-inflammatory decisions. [16]

*Site-directed evaluation of suspected active infection in CGD. [2][15][24]*

| Clinical problem | High-yield evaluation | Decision consequence |
| --- | --- | --- |
| Pulmonary infiltrate, pleuritic pain, hemoptysis, or persistent cough | Chest CT; consider BAL for microbiology and galactomannan testing. [2] | Nodules, halo sign, or cavitation increase concern for invasive mold disease but require microbiologic correlation. [2] |
| Fluctuant node, skin lesion, or deep abscess | Aspiration or drainage for pathogen identification. [15] | Culture-directed management is preferable because CGD involves a characteristic but broad pathogen spectrum. [5][15] |
| Bone pain or suspected osteomyelitis | Site-directed imaging and aspiration or biopsy when feasible. [15] | Look for multifocal and small-bone disease, which is reported more often in CGD. [15] |
| Culture-negative atypical infection | Molecular identification, including 16S rRNA sequencing when indicated. [24] | May identify methylotrophs or other organisms missed by routine methods. [24] |

## Reduce infection burden while assessing candidacy for curative transplantation

Conventional prophylaxis and transplant address different clinical goals.

Conventional CGD management centers on preventing and promptly treating infection while controlling inflammatory complications. Long-term antibacterial prophylaxis, antifungal prophylaxis, and interferon-gamma therapy are established components of conventional management, although specific agent selection and dosing should be individualized with an immunology and infectious-diseases team. [9][10]

Maintain a low threshold to reassess prophylaxis adherence, antimicrobial tolerance, breakthrough pathogen identity, and occult focal infection after any serious infectious event. Prophylaxis does not eliminate risk: patient testimony submitted to the FDA described life-threatening infections occurring approximately every 3.5 years despite prophylactic treatment, underscoring the need for urgent evaluation of new fever or focal symptoms. [1]

Refer patients early to a center experienced in allogeneic hematopoietic stem-cell transplantation. HSCT can cure CGD, but whether every conventionally managed patient should proceed remains debated; transplant decisions should weigh infection history, inflammatory burden, genotype-associated severity, donor options, transplant risk, and patient preference. [11][12][15]

Consider transplantation particularly when severe or recurrent infections, difficult-to-control inflammatory disease, or cumulative treatment burden outweigh the risks of allografting. Durable cure after bone marrow transplantation has been reported, whereas mixed chimerism may coexist with persistent inflammatory manifestations and ongoing treatment needs. [1][11][12]
- Use continuous antibacterial and antifungal prophylaxis as part of conventional long-term management. [9][10]
- Include interferon-gamma in the discussion of conventional management; do not substitute it for diagnostic evaluation of breakthrough fever or focal disease. [9]
- Revisit HSCT after a severe infection, refractory colitis or granulomatous complication, repeated hospitalization, or major prophylaxis intolerance. [11][12]
- Coordinate transplant referral before irreversible organ damage or uncontrolled infection narrows eligibility. [11][12]

### Monitoring priorities

At longitudinal visits, document breakthrough infections by organism and site, antimicrobial adverse effects, inflammatory manifestations, hospitalizations, procedural drainage needs, and functional burden. These data distinguish stable disease on prophylaxis from disease in which transplant risk may be justified. [10][11][12]
- Reassess gastrointestinal symptoms for CGD-associated colitis or obstructive granulomatous disease rather than attributing persistent symptoms solely to medication effects. [16][17]
- Review any new pulmonary symptoms urgently because fungal disease can be difficult to diagnose by culture and may require CT-based evaluation. [2]

*Long-term strategy by disease burden in CGD. [9][10][11][12]*

| Clinical state | Management priority | Escalation trigger |
| --- | --- | --- |
| No active infection with manageable disease burden | Continue long-term antibacterial and antifungal prophylaxis and consider interferon-gamma as conventional management. [9][10] | Breakthrough serious infection, worsening inflammatory disease, or unacceptable treatment burden. [10][11] |
| Breakthrough focal bacterial or fungal infection | Localize infection, obtain microbiology, treat the identified process, and reassess prophylactic strategy. [15][24] | Recurrent, severe, or treatment-refractory infection supports transplant-center assessment. [11][12] |
| Refractory inflammatory colitis or granulomatous obstruction | Exclude active infection and define anatomic disease before intensifying anti-inflammatory treatment. [16][17] | Persistent inflammatory burden despite management warrants discussion of curative HSCT. [11][12] |
| High cumulative disease burden | Obtain expert allogeneic HSCT consultation. [11][12] | Proceed through individualized donor, risk, and benefit assessment; HSCT can cure CGD. [11][12] |

## Common questions

### Can a negative blood culture exclude invasive aspergillosis in CGD?

No. Blood and respiratory cultures are often negative in invasive aspergillosis; obtain chest CT and pursue lower-respiratory sampling when pulmonary findings warrant it. [2]

### When should molecular testing be added to an atypical CGD infection workup?

Add molecular identification when routine culture does not yield a diagnosis despite compatible infection. Methylotroph infections in CGD required 16S rRNA gene sequencing for correct identification. [24]

## References
1. Chronic Granulomatous Disease — www.fda.gov — https://www.fda.gov/media/188989/download
2. Clinical Review — www.fda.gov — https://www.fda.gov/media/89997/download
3. Cutaneous Inflammatory Manifestations of Chronic ... — jamanetwork.com — https://jamanetwork.com/journals/jamadermatology/fullarticle/2820686
4. Defective monocyte oxidative burst predicts infection in alcoholic ... — gut.bmj.com — https://gut.bmj.com/content/gutjnl/early/2016/02/09/gutjnl-2015-310378.full.pdf
5. Chronic granulomatous disease - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/703
6. NMDA receptor modulation of glutamate release in ... — www.thelancet.com — https://www.thelancet.com/article/S2352-3964(19)30520-1/fulltext
7. Update on Clinical Ex Vivo Hematopoietic Stem Cell Gene ... — www.cell.com — https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(20)30618-3
8. Gene Therapy of Chronic Granulomatous Disease — www.cell.com — https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)32350-4
9. Phenotypic Prenatal Diagnosis of Chronic Granulomatous ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/sji.12621
10. Progress in treating chronic granulomatous disease — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/bjh.16939
11. Outcome of chronic granulomatous disease ‐ Conventional ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/pai.13402
12. Conventional treatment vs stem cell transplantation — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/pai.13402
13. Chronic Granulomatous Disease : Pulmon — journals.lww.com — https://journals.lww.com/pulmon/fulltext/2023/05000/chronic_granulomatous_disease.8.aspx
14. Family Clusters of Variant X-linked Chronic Granulomatous... — journals.lww.com — https://journals.lww.com/pidj/fulltext/2009/06000/family_clusters_of_variant_x_linked_chronic.14.aspx
15. Chronic Granulomatous Disease - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/nursing-and-health-professions/chronic-granulomatous-disease
16. Recent advances in chronic granulomatous disease — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2352304219300546
17. Clinical features and outcomes of patients with chronic ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1684118222000962
18. The Diagnostic Approach to Monogenic Very Early Onset ... — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(14)00919-6/fulltext
19. Chronic Granulomatous Disease Presenting as ... — publications.aap.org — https://publications.aap.org/pediatrics/article/134/6/e1727/33203/Chronic-Granulomatous-Disease-Presenting-as
20. C1 PAGE.indd — publications.aap.org — https://publications.aap.org/pediatricsinreview/issue-pdf/826841
21. Case 3: Persistent Fever in an 8-month-old Boy — publications.aap.org — https://publications.aap.org/pediatricsinreview/article/38/3/141/73191/Case-3-Persistent-Fever-in-an-8-month-old-Boy
22. Epidemiology studies in immunotoxicity evaluations — stacks.cdc.gov — https://stacks.cdc.gov/view/cdc/196521/cdc_196521_DS1.pdf
23. Treatment-Resistant Bacterial Lymphadenitis in an ... — publications.aap.org — https://publications.aap.org/pediatricsinreview/article/42/6/339/179835/Treatment-Resistant-Bacterial-Lymphadenitis-in-an
24. Methylotroph Infections and Chronic Granulomatous Disease - Volume 22, Number 3—March 2016 - Emerging Infectious Diseases journal - CDC — wwwnc.cdc.gov — https://wwwnc.cdc.gov/eid/article/22/3/15-1265_article

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.